retatrutide ly3437943 phase 2 trial obesity nejm 2023 for Obesity: Weight-Loss Data Retatrutide, a TRIPLE agonist (GLP1,

EMPA-KIDNEY (Empagliflozin in Patients with Chronic Kidney Disease) showed that in patients with chronic kidney disease, empagliflozin leads to a lower risk of progression of kidney disease [29]

UHPLCMS was used to examine -butylbetaine and l-carnitine levels in clinical and rat blood and urine at different stages of DVT along with analysis of their diagnostic titer and correlation analyses with DVT

Liver health (MASLD/MASH): in people with metabolic dysfunction,associated fatty liver disease, GLP-1s (especially semaglutide) improve steatosis and some histologic endpoints

Carotid artery wall thickening is one of the earliest detectable manifestations of CVD, and is significantly correlated with future CVD events [88]